Modeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits?

Yulan Xiong* and Jianzhong Yu*

Department of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS, United States

Parkinson’s disease (PD) is recognized as the second most common neurodegenerative disorder after Alzheimer’s disease. Unfortunately, there is no cure or proven disease modifying therapy for PD. The recent discovery of a number of genes involved in both sporadic and familial forms of PD has enabled disease modeling in easily manipulable model systems. Various model systems have been developed to study the pathobiology of PD and provided tremendous insights into the molecular mechanisms underlying dopaminergic neurodegeneration. Among all the model systems, the power of Drosophila has revealed many genetic factors involved in the various pathways, and provided potential therapeutic targets. This review focuses on Drosophila models of PD, with emphasis on how Drosophila models have provided new insights into the mutations of dominant genes causing PD and what are the convergent mechanisms.

Keywords: Parkinson’s disease, Drosophila, modeling, leucine-rich repeat kinase 2, α-synuclein, glucocerebrosidase, vacuolar protein sorting 35

INTRODUCTION

Parkinson’s disease (PD) is recognized as the most common movement disorder and the second most common neurodegenerative disorder after Alzheimer’s disease (1). The classical motor features including akinesia, resting tremor, muscle rigidity, and postural imbalance are clinical symptoms in PD patients, and the non-motor features including cognitive impairment, psychiatric symptoms, sleep disorders, autonomic dysfunction, pain, and fatigue also frequently occur (1). The progressive degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta is the cause for the cardinal symptoms (2). Although the majority of PD cases appear to be sporadic, the identification of causative genes that cause familial forms of PD has led to important insights into the pathogenesis of this progressive neurodegenerative disease (3). To date, genes encoding α-synuclein (α-Syn), leucine-rich repeat kinase 2 (LRRK2), Parkin, phosphatase and tensin homolog deleted on chromosome 10-induced putative kinase 2 (PINK1), DJ-1, vacuolar protein sorting 35 (VPS35), and glucocerebrosidase (GBA), among others are associated with genetic forms of PD that closely resemble idiopathic PD (3–8). Among these genes, LRRK2, α-synuclein, GBA, and VPS35 are the dominant traits, and parkin, DJ-1, and PINK1 are the recessive genes. Various model systems have been developed to study the function of PD-causing genes.

Abbreviations: PD, Parkinson’s disease; LRRK2, leucine-rich repeat kinase 2; PINK1, phosphatase and tensin homolog deleted on chromosome 10-induced putative kinase 2; GBA, glucocerebrosidase; DA, dopaminergic; SNpc, substantia nigra pars compacta; EMS, ethyl methanesulfonate; SJ1, synaptojanin 1; EndoA, endophilin A; GSK3β, glycogen synthase kinase 3β; GWAS, genome-wide association studies; LBs, Lewy bodies; α-Syn, α-synuclein; UPS, ubiquitin-protease system; HDAC6, histone deacetylase 6; TRAP1, tumor necrosis factor receptor associated protein-1; ER, endoplasmic reticulum; GlcSph, glucosylceramide (GlCer) and glucosylsphingosine; GD, Gaucher’s disease; UPR, unfolded protein response.
and provided tremendous insights into the molecular mechanisms underlying DA neurodegeneration. While few of genetic models in rodents recapitulate the cardinal features of PD, the power of Drosophila has revealed many genetic factors involved in the various pathways, and provided potential therapeutic targets. Here, we focus on the dominant genes causing PD. We discuss how Drosophila models have provided new insights into the mutations of dominant genes causing PD and what are the convergent mechanisms.

**Drosophila AS A MODEL IN THE STUDY OF PD**

Drosophila melanogaster, as a non-mammalian animal, provides a simple, yet powerful, in vivo system to model PD pathobiology. Drosophila has well-defined nerve system. Particularly, in adult brain, Drosophila has distinct DA neuronal clusters including about 200 DA neurons and displays complicated behaviors mimicking some human behaviors which are DA dependent. Both transgenic and knockout approaches have been utilized to develop Drosophila models of PD. The Drosophila Gal4/UAS system is a powerful tool for targeted transgene expression and has been used to direct selective expression of mutant PD genes. As a simple organism, Drosophila provides great advantages in conducting genome-wide modifier screenings and high-throughput drug screenings. Modifier screenings allow analyses of genome-wide genetic interactions based on the modification of given phenotypes and further identify components of diverse signaling pathways involved in PD pathogenesis.

Several steps can be taken to establish and utilize Drosophila models to study PD:

1. Develop Drosophila lines carrying mutant PD genes,
2. Characterize the phenotypes of the Drosophila models and determine whether they recapitulate the pathogenesis of the disease,
3. Explore the molecular mechanisms underlying the phenotypes,
4. Identify genetic modifiers that suppress or enhance the disease phenotypes through genetic screenings, and dissect the signaling pathways and pathogenic mechanisms involved in pathogenesis,
5. Screen for drug candidates,
6. Study the impact of environmental (e.g., toxin) or aging influence in combination with genetic factors on the pathogenesis of PD.

**MODELING LRRK2-ASSOCIATED PD IN DROSOPHILA**

Mutations in the LRRK2 gene (PARK8, dardarin) is the most common known genetic cause of PD and cause late-onset, autosomal dominant PD with age-related penetrance and clinical features identical to late-onset sporadic PD (9, 10). LRRK2 is a large multifunctional protein about 280 kD. It includes two important enzymatic domains, which are a GTPase domain and a kinase domain, and several protein interaction domains including a LRRK2-specific repeat domain, a leucine-rich repeat, and a WD40 repeat (11–13). Disease causing mutations are found in both enzymatic domains, indicating their importance in disease pathogenesis (11, 12). The most prevalent LRRK2 mutation, G2019S, within the kinase domain, accounts for ~1% of sporadic late-onset PD and 5–6% of familial PD worldwide (14). In North African Arabs and Ashkenazi Jews, the frequency of LRRK2–G2019S mutation can be as high as 30–40% in PD patients (15, 16). Patients with the G2019S mutation exhibit Lewy bodies (LBs) in most cases and incomplete penetrance even at advanced ages (1). However, mutations in the GTPase domain such as R1441 C/G often vary on LB pathology and exhibit nearly complete penetrance (9, 10). This suggests that these pathogenic mutations may cause disease via distinct pathogenic pathways/mechanisms. Tremendous work suggests LRRK2 GTPase and kinase enzyme activities may reciprocally regulate each other to direct LRRK2 functions in diverse cellular signaling pathways (17, 18). LRRK2 is demonstrated to be involved in protein translation, vesicle trafficking, mitochondrial function, lysosomal–autophagy, and cytoskeletal dynamics (13, 18–22). However, how LRRK2 mutations cause neurodegeneration in PD still need to be defined. To this end, various animal models of LRRK2-associated PD have been generated (23–25). Among these models, LRRK2 Drosophila models have provided unique and critical insights on LRRK2 functions (Table 1).

**LRRK2 Drosophila Models**

**LRRK2 Knockout Drosophila Models**

Drosophila has a single human LRRK2 homolog, dLRRK. Residues changed by PD-causing mutations in human LRRK2 are highly conserved in dLRRK (Table 1). To study the physiological function of endogenous LRRK2, dLRRK loss-of-function mutant fly lines have been generated. One major line used in the studies is LRRK (dLRRK) from the Exelixis Collection at the Harvard Medical School. It was generated with piggyBac element insertion in the intron between exon 5 and exon 6 of dLRRK gene. In characterization of dLRRK knockout Drosophila model on PD related pathogenesis, one study reported knockout of dLRRK exhibited a decrease in tyrosine hydroxylase (TH) immunostaining, shrunken DA neurons, and locomotor activity deficits (26), while three studies reported that the homozygous mutant flies developed unchanged number and pattern of DA neurons as well as a normal life span (27–29). Furthermore, the sensitivity of those dLRRK2 knockout flies response to oxidative stress have been examined. Wang et al. showed that dLRRK mutant flies are selectively sensitive to H2O2 (27). By contrast, a report by Imai et al. demonstrated that dLRRK knockout flies are relatively resistant to paraquat and H2O2 treatment (28). Thus, the exact role of dLRRK in PD-related pathogenesis remains elusive. As the majority of studies supported that dLRRK is not required for DA neurons survival and this is consistent with the results from LRRK2 knockout rodents (mice or rats), the general agreement is that LRRK2-induced neuronal toxicity is from a gain-of-function but not a loss-of-function mechanism.

**LRRK2 Transgenic Drosophila Models**

Patients carrying heterozygous or homozygous LRRK2 pathogenic mutations have similar disease risk and progression, supporting
| Genetic manipulations | References | LRRK2 variants | Neurodegeneration | Motor activities/life span | Other functions |
|-----------------------|------------|----------------|------------------|--------------------------|----------------|
| Knockout              | (26)       | dLRRK         | Tyrosine hydroxylase (TH) neurons: no changes TH neurons shrunk TH staining ↓ | Locomotor activity ↓ | ND |
|                       | (27)       | dLRRK         | No changes       | Life span ↓             | Sensitive to hydrogen peroxide, not to paraquat, rotenone, and β-mercaptoethanol |
|                       | (28)       | dLRRK         | TH neurons: no changes; DA content ↑ | Life span ↓ Fertility ↓ Malformed abdomen | Hydrogen peroxide ↓ Paraquat ↓ |
|                       | (29)       | dLRRK         | ND               | Locomotor activity ↓    | ND |
| Transgenic            | (26)       | dLRRK         | No changes       | No changes              | ND |
|                       | (30)       | hLRRK2        | TH neurons ↓ No response to l-DOPA Retinal degeneration | Locomotor activity ↓ Life span ↓ Response to l-DOPA | ND |
|                       |            | hG2019S       | TH neurons ↓↓ No response to l-DOPA Retinal degeneration | Locomotor activity ↓ Life span ↓ Response to l-DOPA | ND |
|                       | (28)       | dLRRK         | No changes       | ND                       | Hydrogen peroxide ↑ Paraquat ↑ |
|                       | (31)       | hLRRK2 (at 29°C) | TH neurons ↓ Retinal degeneration | Locomotor activity: 10 days ↓ 20 days ↑ Life span ↑ Fertility ↑ | Rotenone ↑ |
|                       |            | hI1122V (at 29°C), hy1699C (at 29°C), h2020T (at 29°C) | TH neurons ↓ the most with I2020T Retinal degeneration | Locomotor activity: 10 days ↓ 20 days ↑ Life span ↑ in hY1699C, h2020T Fertility ↑ in hI1122V, h2020T | Rotenone ↑ |
|                       | (32)       | hLRRK2        | No changes       | No changes              | No changes |
|                       |            | hG2019S, hy1699C, hG2385R | TH neurons ↓ | Locomotor activity ↓ Life span ↓ | hG2019S, hG2385R ↓ hy1699C no change |
|                       | (33)       | hLRRK2        | ND               | Locomotor activity: no changes Life span ↓ | Dendritic ends ↓ |
|                       |            | hG2019S       | TH neurons ↓    | Locomotor activity ↓↓ Life span ↓↓ | Dendritic ends ↓ Axon degeneration ↑ |
|                       |            | hR1441C       | ND               | Locomotor activity ↓     | Dendritic ends ↓ |
|                       |            | hG2385R       | Life span ↓     |                         | |
|                       | (34)       | hLRRK2        | ND               | ND                      | Visual function: no changes |
|                       |            | hG2019S       | ND               | ND                      | Visual function ↓ |
|                       |            | hI1122V, hR1441C, hy1383C, hI1915T, h2020T, hG2385R, hG2019/K, 1906M | ND               | ND                      | Visual function: no changes |

(Continued)
LRRK2 functions in PD

LRRK2 Functions in Dendritic Degeneration

Drosophila as a Model to Study PD

Table 1 Continued

| Genetic manipulations | References | LRRK2 variants | Neurodegeneration | Motor activities/life span | Other functions |
|-----------------------|------------|----------------|-------------------|---------------------------|----------------|
| (35)                  | hLRRK2     | ND             | Locomotor activity: no changes | Axon transport: no changes |
|                       | hG2019S    |                |                   |                           |
|                       | hG2019S    |                |                   |                           |
|                       | hR1441C    | ND             | Locomotor activity ↓ | Axon transport ↓ |
|                       | hY1699C    |                |                   |                           |
|                       | dR1069C    | ND             | Locomotor activity ↓ | Axon transport ↓ |
|                       | dY1383C    |                |                   |                           |
| (36)                  | hG2019S    | ND             | Bradykinin, akinesia, hypokinesia, and increased tremor | Proboscis extension response ↓ |
|                       | hI2020T    |                |                   |                           |
|                       | hR1441C    | ND             | No changes        | No changes                |
|                       | hG2019/K   |                |                   |                           |
|                       | 1906M      |                |                   |                           |

ND, not determined; O/E, overexpression; ↑, increased; ↓, decreased.

LRRK2 dominant nature (1) (Table 1). Indeed, in contrast to dLRRK loss-of-function mutant, overexpression of either human LRRK2 (hLRRK2) or dLRRK pathogenic mutations in flies leads to an age-dependent DA neuronal loss and DA-responsive locomotor deficits (28, 30–33, 36, 37). Notably, different LRRK2 mutations cause different phenotypes of the degeneration. One study demonstrated that dopaminergic expression of LRRK2 G2019S led to non-autonomous neurodegeneration in visual system (34). This degeneration is specific to G2019S mutation and dependent on kinase activity. Another report showed that GTPase-COR domain mutations R1441C or Y1699C, but not G2019S, preferentially inhibits axonal transport in Drosophila and causes locomotor deficits (35). This suggests that the defects depend on LRRK2 GTPase activity (35). Recently, Cording et al. reported that expressing either the G2019S or I2020T but not R1441C, or kinase dead LRRK2 in DA neurons reduces proboscis extension response, with bradykinesia, akinesia, and tremor (36). These studies support the possibility that different LRRK2 pathogenic mutations act at distinct pathways and cause disease via distinct pathogenic mechanisms. The LRRK2 transgenic fly models support the gain-of-function of LRRK2 in PD pathogenesis.

**LRRK2** Drosophila Models Reveal LRRK2 Functions in PD

**LRRK2 Functions in Vesicular Trafficking**

Vesicular trafficking has been implicated to play crucial roles in neurodegeneration (38). LRRK2 Drosophila models have provided extensive evidence of potential roles for LRRK2 in various vesicle trafficking processes including endocytosis, ER–Golgi and retromer trafficking, and autophagy–lysosomal pathways (39). dLRRK was reported to localize to the membranes of late endosomes and lysosomes, physically and functionally interacts with Rab7, a key mediator of late endosomal transport and lysosome biogenesis (40). Nonsense alleles in dLRRK induced by ethyl methanesulfonate causes striking defects in the autophagy–lysosomal pathways (41). Furthermore, LRRK2 has been shown to interact with clathrin–light chains to limit Rac1 activation on endosomes (42). Importantly, studies in Drosophila show that LRRK2 phosphorylates endophilin A (EndoA), a central component of synaptic endocytosis, and synaptophysin 1 (SJ1), a synaptic vesicle protein which was recently linked to recessive PD (37, 43–45). LRRK2 regulates EndoA and SJ1 by phosphorylation at synapses, which facilitates synaptic endocytosis through clathrin uncoating at the synaptic terminals. In addition, LRRK2’s role in retromer and ER–Golgi trafficking was highlighted by genetic interactions between LRRK2 and VPS35, Rab7L1, ArfGAP1 in Drosophila (46–49). Moreover, dLRRK has been demonstrated to regulate axonal transport and Golgi outpost dynamics in dendrites through the golgin Lava lamp (35, 50). Taken together, these studies strongly support the roles of LRRK2 in vesicular trafficking processes, which may provide potential mechanisms for α-Syn accumulation in LRRK2-associated PD.

**LRRK2 Functions in Protein Translation Machinery**

The first evidence of LRRK2 function in protein translation was demonstrated in Drosophila (28). In this study, both dLRRK and human LRRK2 can phosphorylate eukaryotic initiation factor 4E-binding protein (4E-BP), a negative regulator of eukaryotic initiation factor 4E-mediated protein translation and a key mediator downstream of mTOR signaling to various stress responses (28). The notion that LRRK2 functions in protein translation was further strengthened by the study from the same group that LRRK2 interacts with the microRNA pathway to regulate protein synthesis (51). However, these studies were done in Drosophila system and need to be extended to mammalian systems. Subsequently, Martin and colleagues, using LRRK2 Drosophila model and human DA neurons, demonstrated that LRRK2 phosphorylates ribosome s15 to regulate protein translation and mediate LRRK2-induced neurodegeneration (52). Recently, Penney et al. showed that LRRK2 targets Furin1 to promote cap-dependent translation, which is required for LRRK2 synaptic function (53). Taken together, these findings support convergent evidence that LRRK2 regulates protein translation machinery directly or indirectly, which could be a potential therapeutic avenue for LRRK2-associated PD.

**LRRK2 Functions in Dendritic Degeneration and Synaptic Dysfunction**

Mutant LRRK2 functions in dendritic degeneration were first revealed by the evidence that LRRK2 G2019S induces...
mislocalization of the axonal protein tau in dendrites and in turn causes dendrite degeneration (33). This may act through tau phosphorylation by the glycogen synthase kinase 3β, which is promoted by LRRK2 G2019S (33). In addition, LRRK2 regulates synaptic morphology through phosphorylation of Futsch at the postsynaptic site of the Drosophila neuromuscular junctions (NMJs) (54). Furthermore, a recent finding indicates that loss of α-Syn promotes calpain-cleaved α-Syn fragments with similar molecular weight (69) (Table 2).

**LRRK2 Drosophila Models as Platforms to Identify Potential Therapeutic Compounds**

The genetic LRRK2 Drosophila models provide promising in vivo platforms for inhibitor identification and validation, and drug development. It has shown that sorafenib, curcumin, or GW5074 significantly suppressed LRRK2 PD-like phenotypes in Drosophila (55, 56). Melatonin attenuates hLRRK2-induced synaptic dysfunction and sleep disorders (57). Although candidate compounds have been used in these studies, they open the possibility of performing compound screens. Recently, Lin et al. identified compounds from the FDA-approved licensed drug library that could rescue LRRK2-induced neurite degeneration, motor disability, and DA neuron loss (58). Of 640 compounds, lovastatin had the highest lipophilicity, which facilitates crossing the blood–brain barrier (58). These studies provide significant steps toward the development of new drugs for treatment of LRRK2-associated PD.

**MODELING α-Syn-ASSOCIATED PD IN Drosophila**

The discovery of the first missense mutation A53T in the SNCA gene in 1997 (59) and the insoluble aggregated α-Syn forms as the major component of LBs, a pathological hallmark of PD (60), heralded a new era in PD research. Since then, more SNCA pathogenic mutations as well as multiplications of SNCA have been identified as genetic causes of PD [review in Ref (61)]. In addition, multiple genome-wide association studies have identified SNCA as a risk factor for sporadic PD (62, 63). These findings revealed a central role of SNCA in PD. SNCA encodes α-Syn protein, a small protein with 140 amino acid residues. It is highly soluble and enriched at presynaptic terminals, where it binds lipids and regulates synaptic vesicle release and it has a propensity of self-aggregate to form oligomeric species and LB-like fibrils (64, 65). Multiple evidence suggest that oligomeric species of α-Syn, which are precursors for higher-order fibrillar aggregates in LBs, are pathogenically toxic and the culprits for neuronal degeneration (66). Recently, prion-like behavior of α-Syn has attracted a lot of attention and been debated in playing an important role in the pathogenesis of PD (67, 68). Although Drosophila have no homolog of SNCA, pathogenic mutations and multiplication of SNCA causing PD with dominant inheritance pattern implicates a toxic gain-of-function mechanism, which led to suitable transgenic modeling in fly by overexpressing wild-type or mutant α-Syn (69) (Table 2).

**α-Syn Transgenic Drosophila Models**

Feany and Bender first developed α-Syn transgenic Drosophila models by overexpressing either wild-type or familial mutants A53T and A30P of human α-Syn using the conventional Gal4/USA expression system (70). These models recapitulate the essential features of PD: adult-onset loss of DA neurons, filamentous intraneuronal inclusions containing α-Syn and locomotor dysfunction (70). In an independent study, Auluck et al. confirmed the phenotypes reported by Feany and Bender (71). In addition to these phenotypes, Chen et al. demonstrated olfactory deficits and elevated anxiety in a α-Syn transgenic Drosophila model expressing A30P (79, 80). There are deficits in two out of three olfactory modalities, odor discrimination and tested-olfactory acuity. A30P expression in dopamine neurons is necessary for both acuity and discrimination deficits. Gajula Balija et al. showed the non-motor symptoms such as an abnormal sleep-like behavior, locomotor deficits, and abnormal circadian periodicity when targeted expression of pre-fibrillar α-Syn mutants in a subset of serotonergic and DA neurons (78). In 2017, the Feany group expended the scope of their previous α-Syn transgenic Drosophila models using a binary expression system, the Q system, which relies on the transcriptional activation by the Neurospora protein QF2 to activate transgene expression (81). This new α-Syn Drosophila model shows robust neurodegeneration, early-onset locomotor deficits, and abundant α-Syn aggregation (81). Although there is some discrepancy over the strength of the phenotypes (73, 82), the α-Syn transgenic Drosophila models are widely used to delineate underlying pathogenic mechanisms and identify novel proteins mediating α-Syn toxicity.

**α-Syn Drosophila Models Reveal α-Syn Functions in PD**

**α-Syn Aggregation and Misfolding in α-Syn-Induced Neurotoxicity**

Accumulating evidence revealed α-Syn aggregation and misfolding plays a central role in the pathogenesis of PD and synucleinopathies. Wild type or mutant α-Syn has been demonstrated to be aggregated as inclusions when overexpressing in flies (70, 71, 81). Structurally engineered α-Syn mutants with an increased oligomerization propensity increase neurotoxicity in Drosophila (76). Truncation of α-Syn contributes to aggregation and LB formation. Expression of α-Syn with a deletion of NAC domain (α-Syn Δ71–82) did not show evidence of α-Syn aggregation and any DA neurodegeneration, suggesting the essential role of NAC domain of α-Syn in aggregation and toxicity (75). By contrast, a C-terminal truncated α-Syn has ability to promote aggregation and enhance neurotoxicity (75). Interestingly, calpain-cleaved α-Syn fragments with similar molecular weight to truncated α-Syn have been identified in the PD/DLB patient.
brains and α-Syn-expressing flies (83). This suggests the physiological and pathological importance of the truncated α-Syn.

Protein quality control systems including molecular chaperones and protein degradation function as a defense mechanism against protein misfolding and aggregation. Identification of suppressors in these systems further supports a critical role of toxic oligomers and aggregation in α-Syn-induced neurotoxicity. Histone deacetylase 6 suppresses α-Syn-induced DA neurodegeneration and promotes the formation of α-Syn inclusions by reducing α-Syn oligomers (84). Auluck et al.

### TABLE 2 | Transgenic Drosophila models of α-Syn-associated Parkinson's disease.

| Transgenic systems | References | α-Syn variants | Neurodegeneration | Motor/non-motor activities and life span | Cellular functions |
|--------------------|------------|----------------|-------------------|-----------------------------------------|--------------------|
| Gal4/UAS system    |            |                |                   |                                         |                    |
| (70)               |            | α-Syn-WT       | Tyrosine hydroxylase (TH) neurons ↓ | Locomotor activity ↓ | Filamentous intraneuronal inclusions containing α-Syn |
|                    |            | A30P A53T      | Retinal degeneration ↑ | | |
| (71)               |            | α-Syn-WT       | TH neurons ↓ | ND | Lewy body- and LN-like inclusions, Hsp70 protected against α-Syn-induced dopaminergic neuronal degeneration |
|                    |            | A30P A53T      | | | |
| (72)               |            | α-Syn-WT       | ND | ND | Phosphorylation of α-Syn at S129 ↑ |
|                    |            | A30P A53T      | | | |
| (73)               |            | α-Syn-WT       | TH neurons: no changes No retinal degeneration | Locomotor activity: no changes | ND |
|                    |            | A30P A53T      | | | |
| (74)               |            | α-Syn-W        | TH neurons ↓ Retinal degeneration ↑ | ND | ND |
|                    |            | S129A          | TH neurons: no changes No retinal degeneration | | |
|                    |            | S129D          | TH neurons ↓ Retinal degeneration ↑ | | |
| (75)               |            | α-Syn-WT       | TH neurons ↓ | ND | α-Syn aggregation ↑ |
|                    |            | α-SynΔ71–82aa  | TH neurons: no changes | | No α-Syn aggregation |
|                    |            | Syn 1–120aa    | TH neurons ↓ | | α-Syn aggregation ↑ |
| (76)               |            | α-Syn-WT       | TH neurons: no changes Locomotor activity: no changes | Soluble oligomers of α-Syn in vitro | |
|                    |            | A30P A53T      | | | |
|                    |            | A65P           | | | |
|                    |            | A30P/A65P/A76P (TP) | TH neurons ↓ | Locomotor activity ↓ | Soluble oligomers of α-Syn in vitro ↑ |
| (77)               |            | α-Syn-WT       | TH neurons ↓ Retinal degeneration ↑ | ND | Soluble oligomers of α-Syn ↑ |
|                    |            | Y125F/Y133F/ Y136 F (YF) | TH neurons ↓ Retinal degeneration ↑ | | Soluble oligomers of α-Syn ↑ |
|                    |            | S129D          | TH neurons ↓ Retinal degeneration ↑ | | Soluble oligomers of α-Syn ↑ |
| (78)               |            | α-Syn-WT       | ND | Sleep behavior normal Circadian locomotor activity defects ↑ | ND |
|                    |            | A53T           | | | |
|                    |            | A30P/A65P/A76P (TP) | ND | Sleep behavior abnormal ↑ Circadian locomotor activity defects ↑ | ND |
| (79)               |            | A30P           | ND | Olfactory deficits | ND |
| (80)               |            | A30P           | TH neurons ↓ | Locomotor activity ↓ Anxiety ↑ | ND |
| Q system           | (81)       | α-Syn-WT       | TH neurons ↓↓ | Locomotor activity ↓↓ | α-Syn aggregation ↑ |

ND, not determined; ↑, increased; ↓, decreased.
demonstrated that increasing the level of chaperone Hsp70 ameliorated the toxicity of α-Syn to DA neurons while a reduction in chaperone activity enhanced α-Syn-induced DA neuronal loss in Drosophila system (71). In addition, decreased level of the mitochondrial chaperone protein tumor necrosis factor receptor associated protein-1 enhanced A53T-α-Syn-induced age-dependent DA neuron loss in flies (85). Molecular chaperones assist proper protein folding and thus protect against α-Syn misfolding and aggregation. If proteins have been misfolded and aggregated, they are cleared by degradation. The ubiquitin-protease system and the autophagy-lysosome systems are two major protein degradation systems. Using Drosophila and cell culture systems, Lee et al. demonstrated that co-expression of ubiquitin can rescue α-Syn-induced neurotoxicity. This neuroprotection is dependent on the formation of lysine 48 polyubiquitin linkage, which is known to target protein degradation (86). This observation is further strengthened by evidence that overexpression of the ubiquitin ligase Nedd4 can rescue α-Syn-induced degenerative phenotype in fly (87). Furthermore, the deubiquitinase Usp8 interacted and partly colocalized with α-Syn, and deubiquitinated K63-linked chains on α-Syn. Knockdown of Usp8 in fly reduced α-Syn levels and α-Syn-induced toxicity (88). In addition, Cullen et al. showed that the defect of cathepsin D, a major lysosomal aspartyl protease, enhanced α-Syn-induced neurodegeneration in vivo in Drosophila (89). Taken together, these results confirmed that protein quality control systems function as a protection mechanism against α-Syn aggregation and misfolding.

**α-Syn Phosphorylation Controls Neurotoxicity Inclusion Formation**

Phosphorylation of α-Syn plays a key role in the PD pathogenesis. Phosphorylation at Ser129 is the one extensively phosphorylated in brain tissues from PD patients and related disorders, suggesting a role for Ser129 phosphorylation in disease pathogenesis (90, 91). In transgenic flies, it has been demonstrated that human α-Syn is phosphorylated at Ser129, and phosphorylation increases with age as DA neurons degenerate, mimicking the pathogenic phenomena in PD patient (72). Later on, Chen and Feany generated transgenic flies carrying the mutations at S129 of α-Syn (S129A to block phosphorylation and S129D to mimic phosphorylation) (74). Using these transgenic lines, they demonstrated phosphorylation of S129 is critical for α-Syn-induced DA neuron degeneration, and blocking S129 phosphorylation increases inclusion formation (74). As increased number of inclusion bodies correlates with reduced toxicity, this study suggested inclusion bodies might have protective function. Recently, the Feany group reported that tyrosine and serine phosphorylation of α-Syn have opposing effects: levels of soluble oligomeric species of α-Syn were increased by serine 129 phosphorylation and decreased by tyrosine 125 phosphorylation, suggesting detrimental effects of S129 phosphorylation and a neuroprotective action of T125 phosphorylation (77). These studies reveal that phosphorylation of α-Syn plays an important role in α-Syn-induced inclusion body formation and DA neurodegeneration.

**α-Syn Functions in Vesicular Trafficking**

The first evidence of α-Syn functions in trafficking in animal models has been reported by Cooper et al. using a combination of a genetic screening in yeast and validation in α-Syn transgenic Drosophila models (92). In this study, Rab1 rescues the neuron loss in the flies (92). Recently, using Drosophila models of α-Syn toxicity, several reports have implicated α-Syn functions in vesicular trafficking particularly through the small GTPase Rab proteins. The endosomal recycling factor Rab1 was demonstrated to modulate synaptic vesicle size, decrease α-Syn aggregation and ameliorate several α-Syn-dependent phenotypes (93). Rab7, regulating trafficking of late endosomes and autophagosomes, and Rab8, modulating post-Golgi vesicle trafficking, rescue the locomotor deficit in α-Syn flies (94, 95). Notably, other PD genes such as LRRK2 and PINK1 have also recently been linked to Rab proteins (48, 96–98). Thus, determination of the precise mechanisms of Rabs-mediated functions in PD pathogenesis is warranted.

**α-Syn Functions in Mitochondrial Dysfunction and Oxidative Stress**

Oxidative stress and mitochondrial dysfunction have been proposed as important causative factors for the progression of PD. Botella et al. found that DA neurons are specifically sensitive to an environmental oxidative insult (hyperoxia) induced oxidative stress. The mutant forms of α-Syn enhanced the toxicity under this stress in the Drosophila model (99). In addition, the co-expression of Cu/Zn superoxide dismutase protects against mutant α-Syn-induced DA neuronal loss (99). The same group also demonstrated that dopamine, which produces reactive oxygen species, might be involved in the α-Syn-induced neurotoxicity through oxidative stress (100). Furthermore, α-Syn-induced neuronal death in Drosophila is enhanced by the mutants that promote glutathione synthesis and conjugation (101). Natural antioxidants attenuate locomotor deficits of α-Syn transgenic flies (102). GPI, an enzyme in glucose metabolism, acts as neuroprotection from α-Syn proteotoxicity in flies (103). Recently, Feany group provided evidence that the interaction of α-Syn with spectrin initiates pathological alteration of the actin cytoskeleton and downstream neurotoxicity, and consequent mitochondrial dysfunction through altered Drp1 localization (81). These results suggest that oxidative stress and mitochondrial dysfunction are features of α-Syn toxicity.

**α-Syn Drosophila Models as Platforms to Identify Potential Therapeutic Compounds**

Based on the functions and mechanisms revealed by α-Syn Drosophila models, several pharmacological interventions have been developed in Drosophila to ameliorate α-Syn toxicity. Geldamamycin, an Hsp90 inhibitor and chaperone inducer, was able to protect α-Syn-expressing neurons in Drosophila (104). Nicotinamide, the principal form of niacin (vitamin B3), has been demonstrated to improve the motor dysfunction in α-Syn transgenic flies through improvement of oxidative mitochondrial dysfunction (105). The dopamine agonists pergolide, bromocriptine, and
TABLE 3 | Drosophila models of glucocerebrosidase (GBA)-associated Parkinson’s disease.

| Genetic manipulations | References | GBA variants | Neurodegeneration | Motor activities/life span | Cellular functions |
|------------------------|------------|--------------|-------------------|---------------------------|--------------------|
| Knockout/knockdown     | (118)      | dGBA1a−/−    | ND                | Locomotor activity: no changes | ND                 |
|                        |            | dGBA1b−/−; dGBA1a,b−/− | Tyrosine hydroxylase (TH) neurons ↓ | Locomotor activity ↓ Life span ↓↓ | Changes in lipid metabolism, accumulation of substrate GlcCer, deficits in lysosomal–autophagy pathway, and abnormality of mitochondria |
|                        | (119)      | dGBA1a,b−/−(ΔTT) | TH neurons: no changes Other neurodegeneration | Locomotor activity ↓ Life span ↓ Memory deficits | Ubiquitinated proteins ↑ α-Syn aggregates ↑ α-Syn expression does not enhance the phenotypes |
|                        | (120, 121)| dGBA1a,b−/−  | TH neurons ↓     | Life span ↓              | GCase activity ↓   |
|                        | (122)      | dGBA1a-RNAi  | TH neurons ↓ Retinal degeneration | Locomotor activity ↓ | Proteinase K-resistant α-Syn accumulation when crossed with α-Syn flies |
| Transgenic             | (120, 121)| hGBA-WT     | No changes        | No changes               | No changes         |
|                        |            | hN370S      | TH level ↓       | Locomotor activity ↓ Life span ↓ | GCase activity ↓ ER stress ↑ |
|                        |            | hL444P      | ND                | ND                        | Neurodevelopment in fly eyes: no changes ER stress: no changes |
|                        | (123)      | hGBA-WT     | ND                | ND                        | Neurodevelopment in fly eyes: no changes ER stress ↓ |
|                        |            | hR120W      | ND                | ND                        | Neurodevelopmental defects in fly eyes ↑ ER stress ↓ |
|                        | (124)      | hGBA-WT     | TH neurons: no changes | Locomotor activity: no changes | ER stress ↑ |
|                        |            | hN370S      | TH neurons ↓     | Locomotor activity ↓ | GCase activity ↓ compared with WT ER stress ↑ |
|                        |            | hL444P      | TH neurons ↓     | Locomotor activity ↓ | GCase activity ↓ compared with WT ER stress ↑ |

ND, not determined; ↑, increased; ↓, decreased.
GBA Drosophila Models

GBA Knockout/Knockdown Drosophila Models

Drosophila has two homologs of the human GBA1 gene, CG31148 and CG31414, which are referred to dGBA1a and dGBA1b, respectively, and shares 32% amino acid identity. These two genes are found on the same chromosome with the CG31413 gene in between and show differential tissue expression. dGBA1b is expressed in the adult brain at low levels as well as in the adult fat body, whereas dGBA1a is predominantly expressed in the adult fly gut but not in the adult brain (FlyAtlas) (125). As GBA mutations in PD show a dominant-negative function, the loss-of-function of GBA was investigated in Drosophila by either knockdown or knockout of dGBA1.

Kinghorn et al. generated dGBA1a, dGBA1b single knockouts (dGBA1aΔ−/−, dGBA1bΔ−/−) or dGBA1a/b double knockouts (dGBA1a/bΔ−/−) using ends-out homologous recombination (118). dGBA1bΔ− and dGBA1a,bΔ− showed a significantly decreased survival and age-dependent locomotor deficits compared with control flies while dGBA1aΔ− showed opposite phenotype with increased survival and without significant effect on climbing ability over time. As dGBA1b is expressed in the adult brain, the study was focusing on dGBA1bΔ− and dGBA1a,bΔ−, both of which showed similar phenotypes (118). Knockout of dGBA resulted in changes in lipid metabolism, accumulation of substrate GlcCer, deficits in lysosomal–autophagy pathway, neurodegeneration, and abnormality of mitochondria. Importantly, mTOR inhibitor rapamycin partially ameliorated the lifespan, locomotion, and abnormality of mitochondria. Consistent with other fly lines, each of which has a minos insertion in dGBA1a and dGBA1b, respectively, and shares 32% amino acid identity. These two genes consistently shown shortened lifespan, behavioral phenotypes (118) and tissue expression.

The clear evidence showed that mutant GCase causes increased ER stress and activated UPR in fly, therefore removal of mutant misfolded GCase by pharmacological chaperones from the ER can recapitulate some PD signs. Using these GBA Drosophila models, further dissection of the molecules involved in these pathways is warranted.

GBA Transgenic Drosophila Models

Heterozygous mutations L444P and N370S are the most common and thought to be dominant-negative mutations of GBA in PD. To investigate GBA functions in PD, transgenic Drosophila expressing human WT, N370S and L444P were generated (120, 121, 124). N370S and L444P transgenic flies exhibited significant decreased GCase activity by 82 and 75%, respectively, compared with GBA WT transgenic flies despite equivalent expression levels of GBA protein (124). N370S and L444P transgenic flies consistently showed shortened life span, a progressive climbing defect, increased level of ER stress and DA neurodegeneration (121, 123, 124). This suggests that those transgenic flies can recapitulate some PD signs.

GBA Drosophila Models Reveal GBA Functions in PD

Two major functions of GBA have been implicated in GBA Drosophila models. One is the function in ER stress and unfolded protein response (UPR) in the ER. Mutant GCase are recognized as misfolded proteins and undergo various degrees of ER associated degradation. The accumulation of misfolded molecules in the ER activate signaling events known as UPR (120). Immunostaining in GBA transgenic flies revealed that a significant amount of GCase colocalized with ER and N370S and L444P caused abnormal aggregates and swelling within the ER (124). To measure UPR activation, an ER stress reporter transgene Xbp1 was used. N370S and L444P GBA mutations induced significant higher Xbp1 level compared to WT GBA flies, suggesting of an increased level of ER stress (120, 124). Another function revealed by GBA fly models is in lysosomal-autophagic pathway. Using LysoTracker and LC3 as markers to monitor lysosomal and autophagic pathology, Kinghorn et al. demonstrated that enlarged and abnormal lysosomes and accumulated Atg8, the fly LC3 homolog, were present in dGBA knockout fly brains (118). The probable downstream effects of lysosomal-autophagic dysfunction could be the accumulation of p62, a marker for lysosomal-autophagic degradation, and polyubiquitinated proteins (118). While these studies provide significant phenotyping investigation on GBA functions, the detailed molecular mechanisms are still largely unknown. Using these GBA Drosophila models, further dissection of the molecules involved in these pathways is warranted.

GBA Drosophila Models as Platforms to Identify Potential Therapeutic Compounds

The clear evidence showed that mutant GCase causes increased ER stress and activated UPR in fly, therefore removal of mutant misfolded GCase by pharmacological chaperones from the ER should at least partially rescue the phenotype. Two chaperones, ambroxol and isofagomine, were previously used to increase amount and lysosomal activity of mutant GCase (126–129). Indeed, ambroxol and isofagomine reduced ER stress, and...
reversed locomotor deficits in GBA mutant flies in vivo (121, 124). This suggests that removal of mutant misfolded GCase from the ER may alleviate PD symptoms. Small chaperones can cross the blood–brain barrier, bind to GCase and stabilize proper folding and ensure delivery to lysosomes. Thus, small chaperones may be applicable for GBA-associated PD.

**MODELING VPS35-ASSOCIATED PD IN Drosophila**

Mutations in the VPS35 gene encoding a core subunit of a heteropentameric complex referred to the retromer have recently emerged as a new cause of late-onset, autosomal dominant familial PD (7, 8). The mutation, D620N, has so far been unambiguously identified to cause PD. The VPS35 protein functions as a core component of the retromer, a protein complex that associates with the endosome to facilitate recycling of transmembrane protein cargoes from both endosome-to-Golgi and endosome-to-plasma membrane transport (130). The retromer is a highly conserved multi-protein complex, the core of which consists of the subunits VPS35, VPS29, and VPS26. The only identifiable VPS35 homolog in Drosophila is encoded by CG5625.

**VPS35 Drosophila Models**

**VPS35 Knockout/Knockdown Drosophila Models**

Two lines of null mutation in VPS35 were generated by either imprecise excision of a P-element inserted at the 5′ end of CG5625 (P[EPgy2]CG5625EY1210) or by a deletion of nearly 2 kb, which removes the first three exons including the translation start site (VPS35^MH20) (Table 4). Both mutants die at late larval or pupal stages, indicating the essential function of VPS35. VPS35-null mutants and RNAi lines (the Vienna Drosophila RNAi Center) were consistently demonstrated to reduce Wingless secretion but not Hedgehog signaling by reducing the recycle of Wntless from endosomes to the trans-Golgi network (131–133). Loss of VPS35 inhibits scavenger receptor ligand endocytosis, causes signaling defects at the NMJ, and leads to over proliferation of blood cells in larvae, which suggests VPS35 has tumor suppressor properties (134). Mechanistically, the endocytic and signaling defects of VPS35 mutants maybe due to VPS35 negatively regulating actin polymerization (134). As these studies were at early stages before mutations of VPS35 has been identified to associate with PD, the PD pathological phenotypes in VPS35 knockout or knockdown mutants were not investigated.

In recent studies, knockdown of VPS35 in Drosophila induced the accumulation of the detergent-insoluble α-Syn in the brain and exacerbated locomotor deficits, compound eye disorganization, and interommatidial bristle loss in α-Syn transgenic flies (135). These findings indicate that the retromer may play a crucial role in α-Syn degradation. The loss of Drosophila VPS35 (dVPS35) affects synaptic vesicle recycling, DA synaptic release and sleep behavior (46). The manipulation of Drosophila LRRK2 dLRRK together with Rab5 and Rab11 improves the VPS35 synaptic phenotypes (46). Taken together, VPS35 knockout/knockdown Drosophila models mimic some pathogenesis of PD, indicating that these fly models could be useful platforms to study VPS35-associated PD.

**VPS35 Transgenic Drosophila Models**

Vacuolar protein sorting 35-linked PD is inherited as a dominant trait, which may imply that the mutation of VPS35 has a

| Genetic manipulations | References | VPS35 variants | Neurodegeneration | Motor activities/life span | Cellular functions |
|-----------------------|------------|----------------|-------------------|---------------------------|-------------------|
| Knockdown             | (139)      | dVPS35 siRNA in α-Syn transgenic fly | ND | Locomotor activity ↓ | Accumulation of the detergent-insoluble α-Syn, cathepsin D activity ↓ Mild eye disorganization |
| Knockout              | (46)       | dVPS35^-^-^-  | Tyrosine hydroxylase (TH) neurons: no changes | ND | Defects on synaptic vesicle recycling, dopaminergic synaptic release and sleep behavior associated with dopaminergic activity; genetic interaction with leucine-rich repeat kinase 2 and Rab5, Rab |
| Transgenic            | (137)      | hVPS35-WT hL774M | TH neurons: no changes | No changes | Sensitive to rotenone: no changes |
|                       |            | hD620N hPS16S | TH neurons ↓ | Locomotor activity ↓ Life span ↓ | Sensitive to rotenone ↑ |
|                       | (138)      | dVPS35-WT dD650N dR550W dL800M hVPS35-WT hD620N hRS24W hL774M | No retinal degeneration | Locomotor activity: no changes Life span: no changes | D620N mutation confers a partial loss of function; VPS35 genetically interacts with Parkin |

*ND, not determined; ↑, increased; ↓, decreased.*
gain-of-function toxicity (Table 4). One study demonstrated that VPS35 D620N transgenic flies led to late-onset loss of DA neurons, locomotor deficits, shortened lifespans, and increased sensitivity to a PD-linked environmental toxin, rotenone (137). However, Malik and colleagues did not find evidence of dominant toxicity from any variants including the pathogenic D620N mutation, even with aging. By a definitive test to determine whether transgene expression can rescue endogenous VPS35 mutant phenotypes, they concluded that the D620N mutation confers a partial loss of function (136). This notion is further supported by other studies in fly or mouse systems that VPS35 DN mutation acts as a dominant-negative function (47, 48, 138, 139).

VPS35 Drosophila Models Reveal VPS35 Functions in PD
To date, VPS35 Drosophila models have revealed three major functions of VPS35 in trafficking pathways in neuronal system. First, VPS35 regulates synaptic vesicle endocytosis through the endosomal pathway. Loss of VPS35 increases the number of synaptic boutons of the NMJ in larval motor neurons (46, 134). It has been demonstrated that VPS35 cooperates with LRRK2 to regulate synaptogenesis, synaptic dynamics and endocytosis, and synaptic vesicle regeneration through the Rab-mediated endocytic pathway (46). Importantly, it in turn regulates DA activity and survival, a key element of PD etiology (46). Second, VPS35 mediates endosomal and Golgi apparatus sorting. Wild-type VPS35, but not a familial PD-associated mutant form, can rescue LRRK2 led to endosomal and Golgi apparatus sorting defects (48). In addition, it has been reported by several groups that VPS35 functions in endosome-to-Golgi retrieval are required for Wingless secretion (131–133). However, whether this function is related to DA neurodegeneration is unknown. Third, VPS35 functions in lysosomal degradation pathway. VPS35 dysfunction impairs the maturation of a lysosome protease cathepsin D in regulating the proteolytic pathway that is important for α-Syn metabolism, and in turn exacerbates neurotoxicity and causes eye degeneration and motor disability (135). These findings indicate that VPS35 may play a crucial role in α-Syn degradation and might thereby contribute to the pathogenesis of the disease. While it remains unclear if these functions are causally for DA neurodegeneration caused by VPS35 PD mutant, these studies have provided important insights into cellular pathways that are perturbed by VPS35 mutations in neurons.

CONVERGENT MECHANISMS
Dissecting genetic interaction among PD genes will be crucial to establish convergent functional pathways of these genes or risk factors. Drosophila as a classic genetic model provides powerful tools to study genetic interactions between different genes. Genetic dissection revealed that LRRK2 interacts with other PD genes or risk factors such as Parkin, DJ-1, PINK1, VPS35, and RAB7L (31, 46–48) and implicated several potential functions. Genetic interaction between LRRK2 and VPS35 or Rab7L indicates LRRK2 function in retromer and lysosomal pathways (46–48). Genetic interaction between LRRK2 and Parkin or PINK1 indicates LRRK2 function in mitochondria dysfunction and also suggests that dominant PD genes may act via common pathways with the recessive PD genes (31). Furthermore, VPS35 genetically interacts with Parkin but interestingly not with PINK1 (136). Notably, α-Syn, LRRK2, and PINK1 have recently been linked to Rab proteins (48, 92–98), and the manipulation of Drosophila LRRK2 dLRRK together with Rab5 and Rab1 improves the VPS35 synaptic phenotypes (46). All the studies are convergent to implicate an important emerging role for defects in trafficking pathways. The accumulation of altered proteins including α-Syn and damaged mitochondria ultimately might overwhelm the disposal mechanisms, in turn cause DA neurodegeneration.

CONCLUDING REMARKS
While the rodent models generally attack more attention and efforts on studying human disorders because of their high conservation of basal ganglia circuit with human, modeling PD in rodents using genetics has been viewed as difficult (23, 140). The rodent models of PD could not fulfill all the key features of PD (140). The reason that the rodents are “imperfect” for modeling PD might be compensatory mechanisms in the rodents, and/or incomplete penetrance of some PD gene mutations such as LRRK2 disease causing mutations in human, and/or the combination effects of non-cell-autonomous and cell-autonomous processes (23, 140).

To this caveat, Drosophila models have provided significant contributions to our understanding of the mechanisms of PD pathogenesis in a comparatively short time frame and cost effective mode. Overexpression of PD dominant traits (LRRK2 and α-Syn) or knockout of dominant-negative genes (GBA and VPS35) in fly has been consistently demonstrated to mimic the essential PD signs such as DA neurodegeneration and behavioral deficits. Based on these fly models, genetic modifiers and small molecular compounds have been rapidly identified. Moreover, the combination roles of the genetic and environmental factors such as oxidative stress have been explored in PD. The important functions of LRRK2 in trafficking and protein translation, the critical contribution of α-Syn aggregation and phosphorylation, were initially discovered in fly. The Drosophila models so far are one of the major model systems to study GBA function in PD. Thus, the use of Drosophila models opened tremendous opportunities to explore the basic function of disease causing genes and to model the disease pathogenesis.

However, Drosophila is a relatively simple model organism, far less complex brain circuit than humans. For example, Drosophila does not have α-Syn homolog and a true human LRRK2 homolog, α-Syn neuropathology in the form of LBs is the hallmark of PD pathogenesis. Whether α-Syn is required for developing PD models has been raised. In addition, Drosophila has limited cell death effectors. Some aspects of human diseases may not be evident in fly. Thus, validation of findings from Drosophila to mammalian systems, including rodent models, human postmortem tissue,
and human DA neuronal cultures, is warranted. Therefore, the strategy would be to identify the basic aspects of the underlying disease mechanisms using simple organism model systems such as *Drosophila* and further characterize and validate the findings in mammalian conditions.

**AUTHOR CONTRIBUTIONS**

YX and JY analyzed the literatures and wrote the manuscript.

**REFERENCES**

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. *Lancet* (2009) 373:2055–66. doi:10.1016/S0140-6736(09)60492-X
2. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. *J Clin Invest* (2006) 116:1744–54. doi:10.1172/JCI29178
3. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson’s disease. *Annu Rev Genomics Hum Genet* (2011) 12:301–25. doi:10.1146/annurev-genom-082410-101440
4. Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C, Lincoln SJ, Lepretre F, Hulham MM, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. *Am J Hum Genet* (2011) 89:398–406. doi:10.1016/j.ajhg.2011.08.009
5. Scholz SW, Jeon BS. GBA mutations and Parkinson disease: when genotype meets phenotype. *Neurology* (2015) 84:866–7. doi:10.1212/01.wnl.00000000001321
6. Vilarino-Guell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J, et al. DNAJC13 mutations in Parkinson disease. *Hum Mol Genet* (2014) 23:1794–801. doi:10.1093/hmg/ddt550
7. Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, et al. VP35 mutations in Parkinson disease. *Am J Hum Genet* (2011) 89:162–7. doi:10.1016/j.ajhg.2011.06.001
8. Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, et al. A mutation in VP35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. *Am J Hum Genet* (2011) 89:168–75. doi:10.1016/j.ajhg.2011.06.008
9. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes Parkinson disease. *Am J Hum Genet* (2011) 89:551–60. doi:10.1016/j.ajhg.2011.06.002
10. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln SJ, et al. LRRK2 pathobiology in Parkinson disease. *Annu Rev Genomics Hum Genet* (2011) 12:301–25. doi:10.1146/annurev-genom-082410-101440
11. Cookson MR. LRRK2 pathways leading to neurodegeneration. *Curr Neurol Neurosci Rep* (2015) 15:42. doi:10.1007/s11911-015-0564-y
12. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson's disease. *Neuroradiology* (2014) 131:554–65. doi:10.1111/jnc.12949
13. Vilarino-Guell C, Xiong Y, Tani SQ, Dawson VL, Vogel RL, Finney EM, et al. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. *Hum Mol Genet* (2012) 21:163–74. doi:10.1093/hmg/ddr451
14. Xiong Y, Coombes CE, Kilaru A, Li X, Gitter AD, Bowers WJ, et al. GTPase activity plays a key role in the pathobiology of LRRK2. *PLoS Genet* (2010) 6:e1000902. doi:10.1371/journal.pgen.1000902
15. Xiong Y, Dawson TM, Dawson VL. Models of LRRK2-associated Parkinson's disease. *Adv Neurobiol* (2017) 12:163–91. doi:10.1007/978-3-319-49960-7_9
16. Xiong Y, Neifert S, Karuppagounder SS, Liu Q, Stankowski JN, Lee BD, et al. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. *Proc Natl Acad Sci U S A* (2018) 115(7):1635–40. doi:10.1073/pnas.1712648115
17. Xiong Y, Neifert S, Karuppagounder SS, Stankowski JN, Lee BD, Grima JC, et al. Overexpression of Parkinson's disease-associated mutation LRRK2 G2019S in mouse forebrain induces behavioral deficits and alpha-synuclein pathology. *eNeuro* (2017) 4(2). doi:10.1523/EJNMO.00044-17.2017
18. Lee SB, Kim W, Lee S, Chung J. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in *Drosophila*: *Biochim Biophys Res Commun* (2007) 358:534–9. doi:10.1016/j.bbrc.2007.04.156
19. Wang D, Tang B, Zhao G, Pan Q, Xia K, Bodmer R, et al. Dispensable role of *Drosophila* ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. *Mol Neurodegener* (2008) 3:3. doi:10.1186/1750-1323-3-3
20. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Ota E, et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in *Drosophila*. *EMBO J* (2008) 27:2423–43. doi:10.1038/emboj.2008.163
21. Tair LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic loss. *Nat Neurosci* (2009) 12:1129–35. doi:10.1038/nn.2372
22. Liu Z, Wang X, Yu Y, Li X, Wang T, Jiang H, et al. A *Drosophila* model for LRRK2-linked parkinsonism. *Proc Natl Acad Sci U S A* (2008) 105:2693–8. doi:10.1073/pnas.0708452105
23. Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, Imai Y, et al. Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PNK-1 in a *Drosophila* melanogaster model of Parkinson’s disease. *Hum Mol Genet* (2009) 18:4390–404. doi:10.1093/hmg/ddp394
24. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in *Drosophila*. *J Neurosci* (2009) 29:11257–62. doi:10.1523/JNEUROSCI.2375-09.2009
25. Lin CH, Tais PI, Wu RM, Chien CT. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3δ. *J Neurosci* (2010) 30:13138–49. doi:10.1523/JNEUROSCI.1737-10.2010
26. Hindle S, Afarsi F, Stark M, Middleton CA, Evans GJ, Sweeney ST, et al. Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to...
non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy. *Hum Mol Genet* (2013) 22:2129–40. doi:10.1093/hmg/ddt219.

35. Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. *Nat Commun* (2014) 5:2545. doi:10.1038/ncomms6245.

36. Cording AC, Shiaelis N, Petridi S, Middleton CA, Wilson LG, Elliott CJH. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson’s disease. *Hum Mol Genet* (2016) 25:3565–82. doi:10.1093/hmg/ddw552.

37. Linhart R, Wong SA, Cao J, Tran M, Huynh A, Ardrey C, et al. Vacuolar protein sorting machinery facilitates axonal transport and cell viability in a Drosophila model of Parkinson’s disease. *Nature* (2014) 539:207–16. doi:10.1038/nature20414.

38. MacLeod DA, Rhinn H, Liu M, Lu B. Pathogenic LRRK2 negatively regulates the dynamic profile of dendritic Golgi outposts through the golgin Lava lamp. *J Cell Biol* (2014) 205:1695–704. doi:10.1083/jcb.201401064.

39. Inoshita T, Arano T, Hosaka Y, Meng H, Umezaki Y, Kosugi S, et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. *Hum Mol Genet* (2013) 22:2129–40. doi:10.1093/hmg/ddx179.

40. Islam MS, Nolte H, Jacob W, Ziegler AB, Putz S, Grosjean Y, et al. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson’s disease. *Hum Mol Genet* (2016) 25:3565–82. doi:10.1093/hmg/ddw552.

41. Schreij AM, Chaineau M, Ruan W, Lin S, Barker PA, Fon EA, et al. LRRK2 regulates retrograde synaptic compensation at the neuromuscular junction. *Nat Commun* (2014) 5:5245. doi:10.1038/ncomms6245.

42. Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, et al. Ribosomal protein S6 phosphorylation mediates Lrrk2 neurodegeneration in Parkinson’s disease. *Cell* (2014) 157:472–85. doi:10.1016/j.cell.2014.01.064.

43. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. *Nature* (2010) 466:637–41. doi:10.1038/nature09191.

44. Soukup SF, Kuenen S, Vanhauwaert R, Manetsberger J, Hernandez-Diaz S, et al. Phosphorylation of alpha-synuclein characteristic of synucleinopathy disease models. *Autophagy* (2016) 13:3936–44. doi:10.1080/14770514.2016.1286440.

45. Lin CH, Lin HI, Chen ML, Lai TT, Cao LP, Farrer MJ, et al. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity. *Hum Mol Genet* (2016) 25:1906–17. doi:10.1093/hmg/ddw068.

46. Inoshita T, Arano T, Hosaka Y, Meng H, Umezaki Y, Kosugi S, et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. *Hum Mol Genet* (2013) 22:2129–40. doi:10.1093/hmg/ddx179.

47. Linhart R, Wong SA, Cao J, Tran M, Huynh A, Ardrey C, et al. Vacuolar protein sorting machinery facilitates axonal transport and cell viability in a Drosophila model of Parkinson’s disease. *Nature* (2014) 539:207–16. doi:10.1038/nature20414.

48. MacLeod DA, Rhinn H, Liu M, Lu B. Pathogenic LRRK2 negatively regulates the dynamic profile of dendritic Golgi outposts through the golgin Lava lamp. *J Cell Biol* (2014) 205:1695–704. doi:10.1083/jcb.201401064.

49. Xiong Y, Yuan C, Chen R, Dawson TM, Dawson VL. ArfGAP1 is a GTPase activating protein for LRRK2 kinase attenuation of PARK8 proteinopathy in Drosophila. *Autophagy* (2014) 10:657–63. doi:10.4161/autophagy.29291.

50. Peng M, Qiu J, Chen J, Hou J, Sun G, Cheng X, et al. LRRK2 regulates autophagic protein degradation at presynaptic terminals. *Acta Neuropathol* (2017) 134:819–38. doi:10.1007/s00401-017-1755-1.

51. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. *Nature* (2010) 466:637–41. doi:10.1038/nature09191.

52. Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, et al. Ribosomal protein S6 phosphorylation mediates LRRK2 neurodegeneration in Parkinson’s disease. *Cell* (2014) 157:472–85. doi:10.1016/j.cell.2014.01.064.

53. Penneny J, Tsurudome K, Liao EH, Kauwe G, Gray L, Yanagita A, et al. LRRK2 regulates retrograde synaptic compensation at the Drosophila neuromuscular junction. *Nat Commun* (2016) 7:12188. doi:10.1038/ncomms12188.
Xiong and Yu

Drosophila as a Model to Study PD

89. Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, et al. Cathepsin D and cathepsin L modulate alpha-synuclein-induced defects in synaptic transmission and behavior. *Hum Mol Genet* (2015) 24:1077–87. doi:10.1093/hmg/ddv521

90. Dinter E, Saridakis T, Nippold M, Plum S, Diederichs L, Konnig D, et al. Rab7 induces clearance of alpha-synuclein aggregates. *J Neurochem* (2016) 138:758–74. doi:10.1111/jnc.13712

91. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, et al. The mitochondrial chaperone protein TRAP1 mitigates alpha-synuclein accumulation and toxicity in Parkinson's disease models. *EMBO J* (2018) 37:65–75. doi:10.15252/embj.201791593

92. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Neurobiol Dis* (2014) 62:644–54. doi:10.1016/j.nbd.2013.11.036

93. Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. *EMBO J* (2009) 28:3256–68. doi:10.1038/emboj.2009.257

94. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. *J Clin Invest* (2009) 119:3257–65. doi:10.1172/JCI39088

95. Ordonez DG, Lee MK, Feany MB. Alpha-Synuclein induces mitochondrial dysfunction and neuronal death. *J Neurochem* (2007) 100:1725–38. doi:10.1111/j.1471-4159.2007.04288.x

96. Lee FK, Wong AK, Lee YW, Wan OW, Chan HY, Chung KK. The role of histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein neurotoxicity by geldanamycin in *Drosophila* model of Parkinson's disease. *J Neurosci* (2008) 28:465–72. doi:10.1523/JNEUROSCI.0778-07.2008

97. Purlyte E, Dhekne HS, Sarhan AR, Gomez R, Lis P, Wightman M, et al. Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. *EMBO J* (2018) 37(1):1–18. doi:10.15252/embj.201798099

98. Steger M, Tonelli E, Go G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. *Elife* (2016) 5:e12813. doi:10.7554/eLife.12813

99. Botella JA, Bayersdorfer F, Schnewly S. Superoxide dismutase overexpression protects dopaminergic neurons in a *Drosophila* model of Parkinson's disease. *Neurobiol Dis* (2008) 30:65–73. doi:10.1016/j.nbd.2007.11.013

100. Bayersdorfer F, Voigt A, Schnewly S, Botella JA. Dopamine-dependent neurodegeneration in familial and sporadic Parkinson's disease. *Neurobiol Dis* (2010) 40:113–9. doi:10.1016/j.nbd.2010.02.012

101. Trinh K, Moore K, Wes PD, Muchowski PJ, Dev J, Andrews L, et al. Induction of the phase II detoxification pathway suppresses neuron loss in *Drosophila* models of Parkinson's disease. *J Neurosci* (2008) 28:1725–38. doi:10.1523/JNEUROSCI.4778-07.2008

102. Jahromi SR, Haddadi M, Shivanandappa T, Ramesh SR. Attenuation of neurodegeneration by natural antioxidants of *Decalepis hamiltonii* in transgenic *Drosophila* model of Parkinson's disease. *Neuroscience* (2015) 293:136–50. doi:10.1016/j.neuroscience.2015.02.048

103. Knight AL, Yan X, Hamamichi S, Ajuri RR, Mazzulli JR, Zhang MW, et al. The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. *Cell Metab* (2014) 20:45–57. doi:10.1016/j.cmet.2014.04.019

104. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of [alpha]-synuclein neurotoxicity by geldanamycin in *Drosophila*. *J Biol Chem* (2005) 280:2873–8. doi:10.1074/jbc.M412106200

105. Jia H, Li X, Gao H, Feng Z, Li X, Zhao L,  et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a *Drosophila* model of Parkinson's disease. *J Neurosci Res* (2008) 86:2083–90. doi:10.1002/jnr.21650

106. Pendleton RG, Parvez F, Sayed M, Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in *Drosophila melanogaster*. *J Pharmacol Exp Ther* (2002) 300:91–6. doi:10.1124/jpet.300.02.011

107. Yedlapudi D, Joshi GS, Luo D, Todi SV, Dutta AK. Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo *Drosophila* synucleinopathy model. *Sci Rep* (2016) 6:38510. doi:10.1038/srep38510

108. Das B, Rajagopalan S, Joshi GS, Xu L, Luo D, Andersin JK, et al. A novel iron chelator (II) preferring dopamine agonist chelator D-607 significantly suppresses alpha-syn- and MPTP-induced toxicities in vivo. *Neuropharmacology* (2017) 123:88–99. doi:10.1016/j.neuropharm.2017.05.019

109. Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. *Hum Mol Genet* (2006) 15:3012–23. doi:10.1093/hmg/ddi243

110. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. *Science* (2007) 317:516–9. doi:10.1126/science.1143780

111. Sidransky E, Nalls MA, Aysjo JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *N Engl J Med* (2009) 361:1651–61. doi:10.1056/NEJMoa0901281

112. Allafi E, Westbroek W, Sidransky E. The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease. *Neuron* (2017) 91:737–46. doi:10.1016/j.neuron.2017.01.018

113. Erickson AH, Gianns EL, Barranger JA. Biosynthesis of the lysosomal enzyme glucocerebrosidase. *J Biol Chem* (1985) 260:14319–24.

114. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. *Lancet* (2008) 372:1263–71. doi:10.1016/S0140-6736(08)61522-6
115. Barkhuizen M, Anderson DG, Grobler AF. Advances in GBA-associated Parkinson's disease – pathology, presentation and therapies. Neurochem Int (2016) 93:6–25. doi:10.1016/j.neuint.2015.12.004

116. Mazzoli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 146:37–52. doi:10.1016/j.cell.2011.06.001

117. Siebert M, Sidransky E, Westbrook W. Glucocerebrosidase is shaking up the synucleinopathies. Brain (2014) 137:1304–22. doi:10.1093/brain/awu002

118. Kinghorn KJ, Gronke S, Castillo-Quan JI, Woodling NS, Li L, Sirka E, et al. Glucocerebrosidase is shaking up the synucleinopathies. Brain (2014) 137:1304–22. doi:10.1093/brain/awu002

119. Davis MY, Trinh K, Thomas RE, Yu S, Germanos AA, Whitley BN, et al. The contribution of mutant GBA to the development of Parkinson disease in Drosophila melanogaster. J Neurosci (2016) 36:11654–70. doi:10.1523/JNEUROSCI.4527-15.2016

120. Davis MY, Trinh K, Thomas RE, Yu S, Germanos AA, Whitley BN, et al. The contribution of mutant GBA to the development of Parkinson disease in Drosophila melanogaster. J Neurosci (2016) 36:11654–70. doi:10.1523/JNEUROSCI.4527-15.2016

121. Maor G, Cabasso O, Krivoruk O, Rodriguez J, Steller H, Segal D, et al. VPS35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. J Cell Sci (2008) 121:178–85. doi:10.1242/jcs.012336

122. Suzuki M, Fujikake N, Takeuchi T, Kohyama-Koganea A, Nakajima K, Hirabayashi Y, et al. Glucocerebrosidase deficiency in Drosophila results in alpha-synuclein-independent protein aggregation and neurodegeneration. PLoS Genet (2016) 12:e1005944. doi:10.1371/journal.pgen.1005944

123. Suzuki T, Shimoda M, Ito K, Hanai S, Aizawa H, Kato T, et al. Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS One (2013) 8:e69917. doi:10.1371/journal.pone.0069147

124. Sanchez-Martinez A, Beavan M, Gegg ME, Chau KY, Whitworth AJ, and ER stress in Drosophila model of Parkinson's disease. J Neurosci (2016) 36:11654–70. doi:10.1523/JNEUROSCI.4527-15.2016

125. Robinson SW, Herzyk P, Dow JA, Leader DP. FlyAtlas: database of gene expression in the tissues of Drosophila melanogaster. Nucleic Acids Res (2013) 41:D744–50. doi:10.1093/nar/gks1141

126. Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F. Autismoxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurol Sci (2015) 36:233–42. doi:10.1007/s10072-015-2608-0

127. Bendikov-Bar I, Maor G, Filocamo M, Horowitz M, Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis (2013) 50:141–5. doi:10.1016/j.bcmd.2012.10.007

128. Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol (2016) 80:766–75. doi:10.1002/ana.24790

129. Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol (2016) 3:200–15. doi:10.1002/acn3.292

130. Williams ET, Chen X, Moore DJ. VPS35, the retromer complex and Parkinson's disease. J Parkinsons Dis (2017) 7:219–33. doi:10.3233/JPD-161020

131. Belenkaya TY, Wu Y, Tang X, Zhou B, Cheng L, Sharma YV, et al. The retromer complex influences Wnt secretion by recycling wntless from endosomes to the trans-Golgi network. Dev Cell (2008) 14:120–31. doi:10.1016/j.devcel.2007.12.003

132. Franch-Marro X, Wenderl F, Guidato S, Griffith J, Baena-Lopez A, Itasaki N, et al. Wingless secretion requires endosome-to-Golgi retrieval of Wntless/Evi/Sprinter by the retromer complex. Nat Cell Biol (2008) 10:170–7. doi:10.1038/ncll25

133. Port F, Kuster M, Herr P, Furger E, Banziger C, Haussmann G, et al. Wingless secretion promotes and requires retromer-dependent cycling of Wntless. Nat Cell Biol (2008) 10:178–85. doi:10.1038/ncll25

134. Korolchuk VI, Schutz MM, Gomez-Llorente C, Rocha J, Lansu NR, Collins SM, et al. Drosophila Vps35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. J Cell Sci (2007) 120:4367–76. doi:10.1242/jcs.012336

135. Miura E, Hasegawa T, Konno M, Suzuki M, Sugeno N, Fujikake N, et al. VPS35 dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet (2015) 24:6675–86. doi:10.1093/hmg/ddv322

136. Malik BR, Godena VK, Whitworth AJ. VPS35, the retromer complex and Parkinson's disease. J Parkinsons Dis (2015) 5:140. doi:10.3233/JPD-151100

137. Wang HS, Toh J, Lo P, Tio M, Zhao Y, Tan EK. In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila. Mol Brain (2014) 7:3. doi:10.1186/s13041-014-0073-y

138. Ishizu N, Yui D, Hebisawa A, Aizawa H, Cui W, Fujita Y, et al. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice. Hum Mol Genet (2016) 25:4507–17. doi:10.1093/hmg/ddw279

139. Munsie LN, Milnerwood AJ, Seibler P, Beccano-Kelly DA, Tatarnikov I, Khinda J, et al. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease Vps35 mutation p.D620N. Hum Mol Genet (2015) 24:1691–703. doi:10.1093/hmg/ddv582

140. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. VPS35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. J Cell Sci (2007) 120:4367–76. doi:10.1242/jcs.012336

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Xiong and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.